Universal Vision Biotechnology Co Ltd (3218) - Total Liabilities
Based on the latest financial reports, Universal Vision Biotechnology Co Ltd (3218) has total liabilities worth NT$2.07 Billion TWD (≈ $65.27 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Universal Vision Biotechnology Co Ltd cash flow conversion to assess how effectively this company generates cash.
Universal Vision Biotechnology Co Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how Universal Vision Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Universal Vision Biotechnology Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Universal Vision Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Universal Vision Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cadiz Inc
NASDAQ:CDZI
|
USA | $100.27 Million |
|
LiveWire Group Inc.
NYSE:LVWR
|
USA | $27.42 Million |
|
SNDL Inc.
NASDAQ:SNDL
|
USA | $218.77 Million |
|
China Fangda Group Co Ltd
SHE:000055
|
China | CN¥6.99 Billion |
|
Eris Technology
TWO:3675
|
Taiwan | NT$2.18 Billion |
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
China | CN¥105.04 Million |
|
Boston Omaha Corp
NYSE:BOC
|
USA | $177.00 Million |
|
Bigcommerce Holdings Inc
NASDAQ:BIGC
|
USA | $263.77 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down Universal Vision Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Universal Vision Biotechnology Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Universal Vision Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Universal Vision Biotechnology Co Ltd (2003–2024)
The table below shows the annual total liabilities of Universal Vision Biotechnology Co Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$2.01 Billion ≈ $63.23 Million |
+12.27% |
| 2023-12-31 | NT$1.79 Billion ≈ $56.32 Million |
+6.63% |
| 2022-12-31 | NT$1.68 Billion ≈ $52.82 Million |
+17.96% |
| 2021-12-31 | NT$1.42 Billion ≈ $44.77 Million |
+25.80% |
| 2020-12-31 | NT$1.13 Billion ≈ $35.59 Million |
+18.69% |
| 2019-12-31 | NT$951.83 Million ≈ $29.99 Million |
+95.08% |
| 2018-12-31 | NT$487.91 Million ≈ $15.37 Million |
+15.73% |
| 2017-12-31 | NT$421.59 Million ≈ $13.28 Million |
-27.67% |
| 2016-12-31 | NT$582.88 Million ≈ $18.36 Million |
-21.24% |
| 2015-12-31 | NT$740.12 Million ≈ $23.32 Million |
+11.80% |
| 2014-12-31 | NT$662.01 Million ≈ $20.86 Million |
+148.08% |
| 2013-12-31 | NT$266.86 Million ≈ $8.41 Million |
+11.96% |
| 2012-12-31 | NT$238.35 Million ≈ $7.51 Million |
-2.63% |
| 2011-12-31 | NT$244.78 Million ≈ $7.71 Million |
-29.49% |
| 2010-12-31 | NT$347.16 Million ≈ $10.94 Million |
-20.51% |
| 2009-12-31 | NT$436.73 Million ≈ $13.76 Million |
-20.71% |
| 2008-12-31 | NT$550.78 Million ≈ $17.35 Million |
+434.95% |
| 2007-12-31 | NT$102.96 Million ≈ $3.24 Million |
+96.08% |
| 2006-12-31 | NT$52.51 Million ≈ $1.65 Million |
-32.51% |
| 2004-12-31 | NT$77.81 Million ≈ $2.45 Million |
+7.74% |
| 2003-12-31 | NT$72.21 Million ≈ $2.28 Million |
-- |
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical devices, glasses, lens, and vision aid products. It is also involved in leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy services, as well as provides medical and scientific prescription eyeglasses. Furt… Read more